Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049438 | 0.94 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2APPM1BPTPN1 | |
| SCHEMBL6050484 | 0.86 | PPM1B (0.41) | ALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL1826045 | 0.83 | ALDH1A1 (0.40) | ALDH1A1ATML3MBTL1 | |
| SCHEMBL7293847 | 0.82 | NAAA (0.40) | — | |
| SCHEMBL28713959 | 0.81 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2APPM1BPTPN1 | |
| SCHEMBL7296422 | 0.80 | NAAA (0.42) | — | |
| SCHEMBL7286186 | 0.80 | PPM1B (0.41) | ALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL1219868 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL3362858 | 0.79 | SMN1; SMN2 (0.37) | ALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL4574683 | 0.77 | ALDH1A1 (0.41) | ALDH1A1PPM1BPTPN1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814822-B1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | claimed |
| WO-2013120921-A9 | NOVEL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | claimed |
| EP-2814822-A1 | NOVEL PYRROLIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | EP | claimed |
| EP-2054411-B1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2014-08-20 | — | — | EP | claimed |
| US-8802665-B2 | Pyrrolidine derivatives | GENENTECH, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-20130217665-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-08-22 | — | — | US | claimed |
| WO-2013120921-A1 | NOVEL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | claimed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-7858621-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-12-28 | — | — | US | claimed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | claimed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | claimed |
| WO-2000033836-A1 | 5-MEMBERED HETEROCYCLES FOR THE TREATMENT OF HUMAN DISEASES INVOLVING MODULATORS OF SELECTINS | ONTOGEN CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| US-5340823-A | Administering a muscle relaxants for treating parkinson*s disease | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1994-08-23 | — | — | US | claimed |
| EP-0538380-A1 | NEMATICIDAL N-(SULFONYL)PHOSPHONAMIDOTHIOATES AND DITHIOATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992000673-A1 | NEMATICIDAL N-(SULFONYL)PHOSPHONAMIDOTHIOATES AND DITHIOATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-23 | — | — | WO | claimed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | claimed |
| US-4804654-A | INSECTICIDES, MITICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-14 | — | — | US | claimed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | claimed |
| US-4021551-A | INDUCERS FOR INTERFERON FORMATION | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217665-A1 | NOVEL PYRROLIDINE DERIVATIVES | PYCR1, ADCYAP1R1, AVPR1A | ALDH1A1 121/4885MEN1 917/4885KMT2A 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.